Recently, China's anti-cancer drug research has made new breakthroughs. The reporter learned from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences that ASK120067, a new anti-tumor drug with independent intellectual property rights in China, has obtained the clinical trial approval issued by the State Food and Drug Administration and was approved for clinical research.
This drug was jointly developed by Ding Jian and the team of researchers from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and the team of Professor Ding Ke from the Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences and Jiangsu Osei Kang Pharmaceutical Co., Ltd., and is expected to develop into a non-small drug resistance. Cell lung cancer treatment drugs.
It is understood that non-small cell lung cancer accounts for more than 85% of the total number of lung cancer, with high morbidity and high mortality. The first representative of the skin growth factor receptor (EGFR) inhibitors that have been marketed, the drug resistance problem is more prominent, and the EGFR T790M mutation is the most common cause of drug resistance.
The drug developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, is a third-generation EGFR inhibitor designed and synthesized to selectively inhibit EGFR-resistant mutations, inhibit the proliferation of multiple tumor cells containing EGFR mutations, and promote cell proliferation. Apoptosis; but the wild-type EGFR inhibitory activity is weak, showing good selectivity.
In animal experiments, the product shows good anti-tumor activity, can significantly inhibit the growth of a variety of tumor cells containing EGFR mutations, and can effectively inhibit the primary tumor tissue of patients with EGFR T790M mutation in nude mice model. Growth in the middle.
In the field of anti-tumor drug research, in the past, China could only follow or imitate international technology. Nowadays, some of China's research results can be compared with the international leading level. In terms of personalized research, China has carried out research in parallel with the world and strives for certain leadership.
Ding Jian said that the biomarkers of this product are clear, have good safety and metabolic characteristics, and thus have good prospects for drug discovery. (Xinhua)
We are a professional Chinese manufacturer of Bovine Extract; we supply various products of Bovine Extract, such as Bovine Prostate Powder, Bovine Bone Collagen Peptide Powder, Ox Bile Powder, Beef Liver Powder, and can providing product images and basic parameters with each Cattle Extract and Bovine Placenta Extract Powder. We have the perfect after-sales service and technical support. Please do not hesitate to contact us, Look forward to your cooperation!
Bovine Placenta Extract,Bovine Prostate Powder,Bovine Bone Collagen Peptide Powder,Ox Bile Powder
Xi'an Quanao Biotech Co., Ltd. , https://www.quanaobiotech.com